LATE PROGRAMME CHANGES
(Highlighted in red for quick reference)

Friday, 7 October 2016 - 16:00/17:30 – page 43
Room Oslo
EDUCATIONAL SESSION
Emerging concepts in daily management of urothelial tumours
Chair: Aristotelis Bamias, Athens, Greece
Co-Chair: Vincent Khoo, London, UK

16:00 How to select systemic therapy in bladder cancer
Aristotelis Bamias, Athens, Greece

16:30 How to interpret genomic reports in the management of urothelial malignancies
Joaquim Bellmunt, Boston, MA, USA

17:00 Targeted therapies in urothelial malignancies
Jonathan Rosenberg, New York, NY, USA

Friday, 7 October 2016 - 16:00/17:30 – page 44
Room Vienna
JOINT SYMPOSIUM: ESMO-ASCO
Rare cancers
Chairs: Fortunato Ciardiello, Naples, Italy and Daniel Hayes, Ann Arbor, MI, USA

16:00 Introduction
Fortunato Ciardiello, Naples, Italy

16:05 Rare Cancers Europe
Paolo G. Casali, Milan, Italy

16:25 The “paediatric” model for rare cancer research organisation
Gilles Vassal, Villejuif, France

16:45 Clinical trials of rare cancers in the North American Cooperative Groups: The SWOG experience
Anne Schott, Ann Arbor, MI, USA

17:05 The Rare Cancer Genetics Registry in North America
Nora Horick, Boston, MA, USA

17:25 Conclusions and clinical perspectives
Daniel Hayes, Ann Arbor, MI, USA
Friday 7 October - 16:00/17:30 – page 45
Room Berlin
JOINT SYMPOSIUM: ESMO GLOBAL POLICY COMMITTEE-AORTIC-SLACOM-UICC-WHO
Innovative strategies for affordability of value based cancer care
Chairs: Alexandru Eniu, Cluj Napoca, Romania and Ahmed Elzawawy, Port Said, Egypt

16:00 Introduction
Ahmed Elzawawy, Port Said, Egypt

16:05 Core healthcare infrastructure and skills
Richard Sullivan, London, UK

16:20 WHO Essential Medicines List for cancer
Lorenzo Moja, Geneva, Switzerland

16:35 WHO Priority Medical Devices for cancer
Adriana Velazquez Berumen, Geneva, Switzerland

16:50 The realpolitik of reimbursement and pricing: What can be done
Jack Scannell, London, UK

17:05 Workforce requirements
Eduardo Cazap, Buenos Aires, Argentina

17:20 Conclusions / Questions and Answers
Alexandru Eniu, Cluj-Napoca, Romania

Saturday, 8 October 2016 - 09:15/10:30 – page 51 – revised session
Room Madrid
PROFFERED PAPER SESSION
Genitourinary tumours, non-prostate
Chair: Joaquim Bellmunt, Boston, MA, USA
Co-Chair: Bernard Escudier, Villejuif, France

09:15 LBA31 PR - Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study
Matthew Galsky, New York, NY, USA

09:30 LBA32 PR - Pembrolizumab as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study
Arjun Balar, New York, NY, USA

09:45 Immunotherapy will be “THE OPTION” in first and second line urothelial tumours
Laurence Albiges, Villejuif, France

10:00 Chemotherapy will always remain “THE BACKBONE” in urothelial tumours
Viktor Grünwald, Hannover, Germany

10:30 Discussion
11:00 **15190** - Availability of tumour gene expression data facilitates clinical decision-making for patients with advanced cancers  
_Janessa Laskin, Vancouver, BC, Canada_

11:15 **520** - Assessment and comparison of tumor mutational burden and microsatellite instability status in >40,000 cancer genomes  
_David Fabrizio, Cambridge, MA, USA_

11:30 Invited discussant abstracts 15190 and 520  
_Sheila Singh, Toronto, ON, Canada_

11:45 **10** - EPHA2 blockade overcomes primary and acquired resistance to anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC)  
_Giulia Martini, Naples, Italy_

12:00 **15200** - Lurbinectedin (PM01183) exhibits antitumor activity in PARP-inhibitor resistant germline BRCA PDX and lacks cross-resistance with cisplatin  
_Cristina Cruz, Barcelona, Spain_

12:15 Invited discussant abstracts 10 and 15200  
_Joan Seoane, Barcelona, Spain_

---

**Saturday, 8 October 2016 – 13:00/13:45 – page 61**

**Room Vienna**

**KEYNOTE LECTURE**

**Response and resistance to PD-1 blockade therapy**  
_Chair: Rolf A. Stahel, Zurich, Switzerland_

13:00 _Antoni Ribas, Los Angeles, CA, USA_
Melanoma and other skin tumours
Chair: Olivier Michielin, Lausanne, Switzerland
Co-Chair: Paul Lorigan, Manchester, UK

14:45 **LBA39** - (Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma - initial data from the OpACIN trial
*Christian Blank, Amsterdam, Netherlands*

14:57 **LBA40** - Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study of first-line dabrafenib + trametinib vs vemurafenib in patients with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma
*Caroline Robert, Villejuif, France*

15:09 **11110** - Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone
*Antoni Ribas, San Francisco, CA, USA*

15:21 Invited discussant abstracts LBA39, LBA40 and 11110
*Celeste Lebbé, Paris, France*

15:36 **11060** - Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)
*Paolo Ascierto, Naples, Italy*

15:48 **11070** - Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma
*Omid Hamid, Los Angeles, CA, USA*

16:00 Invited discussant abstracts 11060 and 11070
*Olivier Michielin, Lausanne, Switzerland*
Saturday, 8 October 2016 - 14:45/16:15 — page 64
Room Brussels
JOINT SYMPOSIUM: ESMO-SIOP

From childhood to adulthood: Cancer in adolescents and young adults
Chairs: Jean-Yves Douillard, Lugano, Switzerland and Stefan Bielack, Stuttgart, Germany

14:45 Introduction
Jean-Yves Douillard, Lugano, Switzerland

14:50 Adolescents and young adults with cancer: A no man’s land?
Giannis Mountzios, Athens, Greece

15:10 Colorectal cancer in young adults: The focus on hereditary cancer syndromes
Emmanouil Saloustros, Heraklion, Greece

15:30 GU tumours in adolescent and young adults: Focus on germ-cell tumours
Gabriele Calaminus, Bonn, Germany

15:50 Subsequent malignant neoplasms in survivors from childhood cancers
Raoul Reulen, Birmingham, UK

16:10 Conclusions and clinical perspectives
Stefan Bielack, Stuttgart, Germany

Saturday, 8 October 2016 - 16:30/17:30 — page 69
Room Rome
CONTROVERSY SESSION

Should every metastatic prostate cancer patient get germline testing?
Chair: Rob Bristow, Toronto, ON, Canada

16:30 Introduction and first vote
Rob Bristow, Toronto, ON, Canada

16:40 Yes
Elena Castro, Madrid, Spain

17:00 No
Bertrand Tombal, Brussels, Belgium

17:20 Second vote and conclusions
Rob Bristow, Toronto, ON, Canada
CNS tumours
Co-Chairs: Andreas Hottinger, Lausanne, Switzerland and Deborah Blumenthal, Tel Aviv, Israel

326PD - Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM)
Martin van den Bent, Rotterdam, Netherlands

327PD - PD-L1 and IL17 expression in tumor infiltrating lymphocytes are opposite prognostic factors in glioblastoma
Bruno Chauffert, Amiens, France

328PD - Effectiveness of antiangiogenic drugs (ADs) in glioblastoma (GBM) patients (PTS): A metanalysis of randomized clinical trials (RCTs)
Giuseppe Lombardi, Padua, Italy

16:30 Invited discussant abstracts 326PD, 327PD and 328PD
Andreas Hottinger, Lausanne, Switzerland

16:50 Questions to discussant

329PD - Survival of patients with synchronous and metachronous breast cancer and meningioma
Catarina Ribeiro, Lisbon, Portugal

330PD - Temporal muscle thickness (TMT) is an independent prognostic parameter in patients with newly diagnosed brain metastases (BM) of breast cancer (BC)
Anna Sophie Berghoff, Vienna, Austria

331PD - Phase II/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
Christian Grommes, New York, NY, USA

17:00 Invited discussant abstracts 329PD, 330PD and 331PD
Deborah Blumenthal, Tel Aviv, Israel

17:20 Questions to discussant
Sunday, 9 October 2016 - 08:00/09:00 — page 112
Room Rome
CONTROVERSY SESSION
Rectal cancer: What is the optimal time for surgery?
Chair: Karen-Lise Spindler, Aarhus, Denmark

08:00 Introduction and first vote
Karen-Lise Spindler, Aarhus, Denmark

08:10 To wait seems better
Ian Chau, London, UK

08:30 The sooner the better
Jérémie Lefèvre, Paris, France

08:50 Second vote and conclusions
Karen-Lise Spindler, Aarhus, Denmark

Sunday, 9 October 2016 - 09:15/10:45 — page 114
Room Zagreb
SPECIAL SESSION
Adaptive licensing (MAPPs)
Chairs: Paolo G. Casali, Milan, Italy and Bettina Ryll, Uppsala, Sweden

09:15 Regulatory perspectives in MAPPs and the EMA pilot
Francesco Pignatti, London, UK

09:30 MAPPS from the HTA perspective
Sarah Garner, London, UK

09:45 The industry perspective
Thomas Alvin, Brussels, Belgium

10:00 The clinician's perspective: Learning from the rare disease community
Paolo G. Casali, Milan, Italy

10:15 The patient perspective: Patient-centric drug development
Bettina Ryll, Uppsala, Sweden

10:30 Discussion: Challenges
11:00 **LBA42_PR** - Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study
   Giorgio Scagliotti, Orbassano, Italy

11:15 **12080** - Phase 2 study of ceritinib in ALK-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM)
   Enriqueta Felip, Barcelona, Spain

11:30 Invited discussant abstracts LBA42_PR and 12080
   Egbert Smit, Amsterdam, Netherlands

11:45 **LBA43** - Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC): Overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)
   Luis Paz-Ares, Madrid, Spain

12:00 **12010** - Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): Final overall survival (OS) analysis
   Tony S.K. Mok, Hong Kong, China

12:15 Invited discussant abstracts LBA43 and 12010
   Pasi Jänne, Boston, MA, USA
14:45 **4520** - Results of a prospective randomized control 6 vs 12 trial: Is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy?

*Jemma Bhoday, London, UK*

14:57 **4530** - Scheduled use of CEA and CT follow-up to detect recurrence of colorectal cancer: 6-12 year results from the FACS randomised controlled trial

*Sian Pugh, Southampton, UK*

15:09 Invited discussant abstracts 4520 and 4530

*Florence Huguet, Paris, France*

15:24 **LBA20.PR** - Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUMEcolon 1 study

*Eric Van Cutsem, Leuven, Belgium*

15:36 **4540** - A randomized phase III study of napabucasin [BBi608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): The CCTG/AGITG CO.23 trial

*Derek Jonker, Ottawa, ON, Canada*

15:48 **4550** - Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)

*Ryan Corcoran, Boston, MA, USA*

16:00 Invited discussant abstracts LBA20_PR, 4540 and 4550

*Volker Heinemann, Munich, Germany*
16:25 **LBA4** - Patient-Reported Outcomes (PROs) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab (nivo) or Investigator's Choice (IC): CheckMate 141
*Kevin Harrington, London, UK*

16:40 Invited discussant LBA4
*Anthony Chan, Hong Kong, China*

16:50 **LBA46_PR** Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G
*Corey Langer, Philadelphia, PA, USA*

17:05 **LBA8_PR** - KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%
*Martin Reck, Grosshansdorf, Germany*

17:20 Invited discussant LBA46_PR and LBA8_PR
*Jean-Charles Soria, Villejuif, France*

17:35 **LBA7_PR** - CheckMate 026: A Phase 3 trial of nivolumab vs Investigator's Choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage IV/recurrent programmed death ligand 1 (PD-L1) – positive NSCLC
*Mark Socinski, Pittsburgh, PA, USA*

17:50 **LBA44_PR** - Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC
*Fabrice Barlesi, Marseille, France*

18:05 Invited discussant LBA7_PR and LBA44_PR
*Naiyer Rizvi, New York, NY, USA*
Sunday, 9 October 2016 – 16:30/18:00 — page 132
Room Oslo
SPECIAL SYMPOSIUM

Precision medicine in NETs: Myth or reality?
Chair: Rocio Garcia-Carbonero, Madrid, Spain
Co-Chair: Kjell Oeberg, Uppsala, Sweden

16:30 Introduction
Rocio Garcia-Carbonero, Madrid, Spain

16:35 Molecular tumour profiling and upcoming biomarkers: Will they help to deliver personalised medicine?
Timothy Meyer, London, UK

16:50 Minimally invasive surgery: Does it improve precision?
Massimo Falconi, Milan, Italy

17:05 Nuclear medicine: What do novel isotopes add to the treatment of NETs?
Andreas Kjaer, Copenhagen, Denmark

17:20 Targeted drugs: Where are we now?
Marianne Pavel, Berlin, Germany

17:35 Targeted drugs: Where are we heading to?
Eric Raymond, Lausanne, Switzerland

17:50 Conclusions and clinical perspectives
Kjell Oeberg, Uppsala, Sweden

Sunday, 9 October 2016 – 16:30/18:00 — page 134
Room Helsinki
EDUCATIONAL SESSION

Bad luck or bad knowledge? Evidence-based cancer prevention approaches
Chair: Jack Cuzick, London, UK
Co-Chair: Silvia Franceschi, Lyon, France

16:30 Where to give prevention advice
Gauden Galea, Copenhagen, Denmark

17:00 Proven interventions
Silvia Franceschi, Lyon, France

17:30 Unproven interventions
Gareth Evans, London, UK
Sunday, 9 October 2016 - 18:00/19:30 — page 138
Room Zagreb
PATIENT ADVOCACY TRACK
Why do side-effects matter and how to generate data on them
Chair: Ananda Plate, Brussels, Belgium
Co-Chair: Gilliosa Spurrier-Bernard, Clermont-Ferrand, France

18:00 Why the reporting of side-effects is so important
Dimitrios Athanasiou, Athens, Greece

18:15 How differently clinicians, patients and carers perceive side effects
Ananda Plate, Brussels, Belgium

18:30 New drugs that are safe: Pharmacovigilance in oncology
Florence van Hunsel, Hertogenbosch, Netherlands

18:45 Innovative ways to record treatment side effects in clinical trials
To be announced

19:00 Patient networks driving adverse event reporting: The UMC/ MPNE project
Rebecca Chandler, Uppsala, Sweden

19:15 Discussion: What can we as patient advocates do to:
- Increase the safety of our therapies?
- Ensure that side effects are evaluated according to the true impact for patients?

---

Monday, 10 October 2016 - 09:15/10:15 — page 178 — revised session
Room Vienna
PROFFERED PAPER SESSION
NSCLC, metastatic 2
Chair: Tony S.K. Mok, Hong Kong, China
Co-Chair: Fiona Blackhall, Manchester, UK

09:15 LBA45 - Top-line results from SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavikumab Plus Docetaxel in Patients with Previously Treated Stage IIIb/IV Non-Squamous Non Small Cell Lung Cancer
David Spigel, Nashville, TN, USA

09:30 LBA47_PR - Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial
Pasi Jänne, Boston, MA, USA

09:45 12020 - Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Charlotte Leduc, Strasbourg, France

10:00 Invited discussant abstracts LBA45, LBA47_PR and 12020
Tony S.K. Mok, Hong Kong, China
Monday, 10 October 2016 – 09:15/10:45 – page 179
Room Brussels
JOINT SYMPOSIUM: ESMO-DSKO

Perspectives in the registration and use of Big Data and individual molecular profiles
Chair: Fortunato Ciardiello, Naples, Italy and Ulrik Lassen, Copenhagen, Denmark

09:15 Introduction
Fortunato Ciardiello, Naples, Italy

09:20 The value of a large clinical database in testicular cancer
Gedsko Daugaard, Copenhagen, Denmark

09:40 Big Data/cancer epidemiology
Søren Brunak, Copenhagen, Denmark

10:00 International collaboration with molecular profiling (WIN)
Vladimir Lazar, Villejuif, France

10:20 Understanding how immunotherapy works by dissecting the tumour specific T cell response
Sine Reker Hadrup, Copenhagen, Denmark (TBC)

10:40 Conclusions and clinical perspectives
Ulrik Lassen, Copenhagen, Denmark

Monday, 10 October 2016 – 09:30/10:30 – page 180
Room Helsinki

MULTIDISCIPLINARY PATIENT CASES

Targeting the genes is not enough: The patients and tumour behaviour also matter
Chair: Alice Shaw, Boston, MA, USA

09:30 One mutation, many cancers
David Huntsman, Vancouver, BC, Canada

09:40 Resistance mutations and cell context specific adaptive responses
Alice Shaw, Boston, MA, USA

09:50 Considering clonal evolution in breast cancer management
Carlos Caldas, Cambridge, UK

10:00 Discussion
Monday, 10 October 2016 – 11:00/12:00 –page 186
Room Berlin
POSTER DISCUSSION SESSION

Endocrine and neuroendocrine tumours
Co-Chairs: Rocio Garcia Carbonero, Madrid, Spain; Eric Baudin, Villejuif, France and Xavier Matias-Guiu, Lleida, Spain

420PD - NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate: Efficacy, safety, QoL results and subgroup analysis
Jonathan Strosberg, Tampa, FL, USA

421PD - Impact of prior therapies on everolimus treatment in the subgroup of patients with advanced lung neuroendocrine tumors (NET) in the RADIANT-4 trial
Roberto Buzzoni, Milan, Italy

422PD - Integrated placebo-controlled safety analysis from clinical studies of telotristat etiprate for the treatment of carcinoid syndrome
Matthew Kulke, Boston, MA, USA

423PD - Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)
Martin Gutierrez, Hackensack, NJ, USA

11:00 Invited discussant abstracts 420PD, 421PD, 422PD and 423PD
Rocio Garcia Carbonero, Madrid, Spain

11:10 Questions to discussant

424PD - Prevalence of gastroenteropancreatic and lung neuroendocrine tumours in the European Union
Anthony Berthon, Boulogne-Billancourt, France

425PD - Multicentre evaluation of the role of Gallium DOTA-PET (GaPET) imaging in well differentiated bronchial carcinoids (BC): Impact on patients' (pts) management
Angela Lamarca, Manchester, UK

426PD - A population based analysis of outcome of chemotherapy for metastatic pulmonary large cell neuroendocrine carcinomas: Does the regimen matter?
Jules Derks, Maastricht, Netherlands

11:20 Invited discussant abstracts 424PD, 425PD and 426PD
Eric Baudin, Villejuif, France

11:30 Questions to discussant

427PD - Pediatric, adolescent and young adult (PAYA) thyroid carcinoma harbors frequent and diverse targetable genomic alterations including kinase fusions
Siraj Ali, Cambridge, MA, USA

428PD - Damaging germline variants in TSC2 are frequently found among nonsyndromic patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NETs)
Rudinei Linck, Sao Paulo, Brasil

11:40 Invited discussant abstracts 427PD and 428PD
Xavier Matias-Guiu, Lleida, Spain

11:50 Questions to discussant
Monday, 10 October 2016 – 11:00/12:30 – page 185
Room Helsinki
SPECIAL SYMPOSIUM

**Streamlining the equitable delivery of anticancer drugs: Sharing common grounds for a pan-European vision of value**

*Chair: Rosa Giuliani, Rome, Italy*
*Co-Chair: Alexandru Eniu, Cluj-Napoca, Romania*

11:00 Introduction
*Alexandru Eniu, Cluj-Napoca, Romania*

11:05 Equitable and affordable cancer care: Is Europe a union for real?
*Richard Sullivan, London, UK*

11:20 How the European Commission’s HTA initiative and the HTA network can promote consistent assessment of cancer care treatments in the EU
*Andrzej Rys, Brussels, Belgium*

11:35 The EMA’s initiatives to speed up access to valuable cancer drugs: Adaptive pathways and flexible approaches
*Francesco Pignatti, London, UK*

11:50 Industry’s initiatives to reduce inequities and increase access to valuable cancer care: Myth or reality?
*Thomas Alvin, Brussels, Belgium*

12:05 ESMO’s initiatives to reduce disparities in cancer care: Promoting access to valuable drugs focusing on the magnitude of benefit
*Elisabeth de Vries, Groningen, Netherlands*

12:20 Conclusions and clinical perspectives
*Rosa Giuliani, Rome, Italy*
Monday, 10 October 2016 - 11:15/12:50
Room Copenhagen
SPECIAL SESSION
Right or Left metastatic colon cancer: Will the side change your treatment?
Chair: Fortunato Ciardiello, Naples, Italy
Co-Chair: Josep Tabernero, Barcelona, Spain

11:15 Introduction
Fortunato Ciardiello, Naples, Italy

11:20 Sidedness in colon cancer
Heinz Josef Lenz, Los Angeles, CA, USA

11:35 Outcome according to Left vs. Right side in the Panitumumab studies
Marc Peeters, Edegem, Belgium

11:50 Outcome according to Left vs. Right side in the FOLFIRI Cetuximab FIRE 3 study
Volker Heinemann, Munich, Germany

12:00 Outcome according to Left vs. Right side in the FOLFIRI Cetuximab CRYSTAL study
Eric Van Cutsem, Leuven, Belgium

12:10 Outcome in the CALGB 80405
Heinz Josef Lenz, Los Angeles, CA, USA

12:25 Pro Discussion
Dirk Arnold, Lisbon, Portugal

12:35 Contra Discussion
Andrés Cervantes, Valencia, Spain

12:45 Conclusions
Josep Tabernero, Barcelona, Spain
16:30 **LBA6_PR** - Full-dose neoadjuvant anthracycline + ifosfamide chemotherapy is associated with a relapse
free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the
extremities and trunk wall: Interim analysis of a prospective randomized trial
*Alessandro Gronchi, Milan, Italy*

16:45 Invited discussant LBA6_PR
*Axel Le Cesne, Villejuif, France*

16:55 **LBA9_PR** - Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and
cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC)
*Karim Fizazi, Villejuif, France*

17:10 Invited discussant LBA9_PR
*Ronald de Wit, Rotterdam, Netherlands*

17:20 **LBA30_PR** - CABOzantinib versus SUNITINIB (CABOSUN) as initial targeted therapy for patients with
metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203
trial
*Toni Choueiri, Boston, MA, USA*

17:35 Invited discussant LBA30_PR
*Bernard Escudier, Villejuif, France*

17:45 **LBA11_PR** - Phase III trial of sunitinib (SU vs placebo (PBO) as adjuvant treatment for high-risk renal cell
carcinoma (RCC) after nephrectomy (S-TRAC)
*Alain Ravaud, Bordeaux, France*

18:00 Invited discussant LBA11_PR
*Axel Bex, Amsterdam, Netherlands*